Department of Thoracic and Cardiovascular Surgery, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Eur J Cardiothorac Surg. 2024 Sep 2;66(3). doi: 10.1093/ejcts/ezae316.
Invasive mucinous adenocarcinoma exhibits distinct prognostic outcomes compared to non-mucinous adenocarcinoma (ADC). This study investigated and compared the clinical outcomes and prognostic factors of invasive mucinous and non-mucinous ADC patients.
This retrospective study included patients who underwent curative surgery for ADC between 2011 and 2021. Patient characteristics were balanced using propensity score matching. Cumulative incidence was analysed to evaluate cancer recurrence incidence, and the Kaplan-Meier method was used to calculate overall survival (OS) for each group.
A total of 6101 patients were included. After matching, the non-mucinous group and mucinous groups comprised 798 and 408 patients, respectively. The patients in the mucinous group had a lower recurrence incidence than those in the non-mucinous group (P = 0.014). The recurrence incidence in the mucinous group was between those of grades 1 (P = 0.011) and 2 (P = 0.012) and the OS rates were comparable to those of grades 2 (P = 0.6) and 3 (P = 0.2). Multivariable analysis revealed that the maximal standardized uptake value [hazard ratio (HR): 1.13, P = 0.11] and progressed pathological stages (pStage II, HR: 3.9, P = 0.028; pStage III, HR: 8.33, P = 0.038) served as adverse prognostic factors for the mucinous group.
Patients with mucinous ADC demonstrated lower recurrence incidence and similar OS rates compared to those with non-mucinous ADC. The recurrence incidence of mucinous ADC was between those of International Association for the Study of Lung Cancer grades 1 and 2, with the OS rates comparable to those of grades 2 and 3.
None.
浸润性黏液腺癌与非黏液性腺癌(ADC)相比,具有明显不同的预后结果。本研究旨在探讨和比较浸润性黏液性和非黏液性 ADC 患者的临床结局和预后因素。
本回顾性研究纳入了 2011 年至 2021 年间接受 ADC 根治性手术的患者。采用倾向评分匹配平衡患者特征。采用累积发生率分析评估癌症复发发生率,采用 Kaplan-Meier 法计算各组的总生存期(OS)。
共纳入 6101 例患者。匹配后,非黏液组和黏液组分别包括 798 例和 408 例患者。黏液组的复发率低于非黏液组(P=0.014)。黏液组的复发率介于 1 级(P=0.011)和 2 级(P=0.012)之间,OS 率与 2 级(P=0.6)和 3 级(P=0.2)相当。多变量分析显示,最大标准化摄取值(HR:1.13,P=0.11)和进展性病理分期(pStage II,HR:3.9,P=0.028;pStage III,HR:8.33,P=0.038)是黏液组的不良预后因素。
与非黏液性 ADC 相比,黏液性 ADC 患者的复发率较低,OS 率相似。黏液性 ADC 的复发率介于国际肺癌研究协会(IASLC)1 级和 2 级之间,OS 率与 2 级和 3 级相当。
无。